Literature DB >> 8878502

Clinical evaluation of chemosensitivity testing for patients with colorectal cancer using MTT assay.

H Yamaue1, H Tanimura, M Nakamori, K Noguchi, M Iwahashi, M Tani, T Hotta, K Murakami, K Ishimoto.   

Abstract

PURPOSE: Colorectal cancer is one of the tumors most refractory to treatment by chemotherapy. The chemosensitivity test should be performed to individualize the chemotherapy for patients with colorectal cancer, which is less sensitive for anticancer drugs. The present study was designed to determine the chemosensitivity in fresh human colorectal cancer, using highly purified tumor cells, and the correlation of this sensitivity with clinical response.
METHODS: We determined the chemosensitivity for cisplatin, mitomycin C, adriamycin, and 5-fluorouracil in vitro in 93 fresh human colorectal cancers using the MTT assay and performed chemotherapy according to results of the MTT assay.
RESULTS: Inhibition rate of tumor cells for cisplatin was higher than those for other drugs. Fifteen patients who have evaluable lesions received chemotherapy according to results of the MTT assay. Clinical responses were obtained in 5 of 15 patients, and the inhibition rate for cisplatin was higher in responders than in nonresponders.
CONCLUSIONS: It is suggested that the chemotherapy according to results of the MTT assay is effective in patients with colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8878502     DOI: 10.1007/bf02054057

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  9 in total

1.  Metastatic lung disease to the central nervous system: in vitro response to chemotherapeutic agents.

Authors:  Jane W Marsh; Maryann Donovan; Dennis R Burholt; Lisa D George; Paul L Kornblith
Journal:  J Neurooncol       Date:  2004-01       Impact factor: 4.130

2.  P-glycoprotein-expressing tumor cells are resistant to anticancer drugs in human gastrointestinal cancer.

Authors:  T Hotta; H Tanimura; M Iwahashi; M Tani; T Tsunoda; K Noguchi; S Mizobata; K Arii; H Terasawa; M Nakamori; H Yamaue
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

3.  Intraoperative radiation therapy for a patient with bulky disease of mesenteric non-Hodgkin's lymphoma.

Authors:  H Yamaue; H Tanimura; H Terasawa; Y Nakatani; T Tsunoda; M Tani; M Iwahashi
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

4.  Successful immunochemotherapy for patients with malignant mesothelioma: report of two cases.

Authors:  M Tani; H Tanimura; H Yamaue; S Mizobata; M Yamamoto; M Iwahashi; K Ura; Y Nagai; T Tsunoda; H Wakasaki; K Nanjo; K Fujino; S Yukawa
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

Review 5.  Prediction of individual response to anticancer therapy: historical and future perspectives.

Authors:  Florian T Unger; Irene Witte; Kerstin A David
Journal:  Cell Mol Life Sci       Date:  2014-11-12       Impact factor: 9.261

6.  Capecitabine inhibits epithelial-to-mesenchymal transition and proliferation of colorectal cancer cells by mediating the RANK/RANKL pathway.

Authors:  Minghai Shao; Caiping Jiang; Changhui Yu; Haijian Jia; Yanli Wang; Xinli Mao
Journal:  Oncol Lett       Date:  2022-01-27       Impact factor: 2.967

7.  Antibiofilm and anticancer activities of unripe and ripe Azadirachta indica (neem) seed extracts.

Authors:  Kartik Chandra Guchhait; Tuhin Manna; Manas Barai; Monalisha Karmakar; Sourav Kumar Nandi; Debarati Jana; Aditi Dey; Suman Panda; Priyanka Raul; Anuttam Patra; Rittwika Bhattacharya; Subhrangsu Chatterjee; Amiya Kumar Panda; Chandradipa Ghosh
Journal:  BMC Complement Med Ther       Date:  2022-02-14

Review 8.  Tumor Chemosensitivity Assays Are Helpful for Personalized Cytotoxic Treatments in Cancer Patients.

Authors:  Engin Ulukaya; Didem Karakas; Konstantinos Dimas
Journal:  Medicina (Kaunas)       Date:  2021-06-19       Impact factor: 2.430

9.  Exploratory phase II trial in a multicenter setting to evaluate the clinical value of a chemosensitivity test in patients with gastric cancer (JACCRO-GC 04, Kubota memorial trial).

Authors:  Nobuhiko Tanigawa; Hiroki Yamaue; Shigekazu Ohyama; Shinichi Sakuramoto; Takao Inada; Yasuhiro Kodera; Yuko Kitagawa; Kenji Omura; Masanori Terashima; Yuh Sakata; Atsushi Nashimoto; Toshiharu Yamaguchi; Keisho Chin; Eiji Nomura; San-Woong Lee; Masahiro Takeuchi; Masashi Fujii; Toshifusa Nakajima
Journal:  Gastric Cancer       Date:  2015-09-18       Impact factor: 7.370

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.